Prof Andrew Wei (MBBS, PhD) co-leads the acute myeloid leukemia program at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne, Australia.

He is a Metcalf Family research fellow and NHMRC investigator at WEHI  (the Walter and Eliza Hall Institute of Medical Research) whose laboratory investigates novel approaches to treat AML.

His interests include BH3-mimetics, targeting MRD and the role of TP53 in AML. Prof Wei has been principal investigator for numerous commercially sponsored and investigator-initiated clinical trials and sits on the steering committee for multiple global advisory boards developing new drugs in the field of AML. Prof Wei has also successfully mentored numerous clinical fellows to lead nationwide clinical trials in AML.


Selected publications from Prof Andrew Wei

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. New Engl J Med 2020;383(26):2526-2537.PMID: 33369355

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med 2020;383(7):617-629.PMID: 32786187

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD,….., Wei A et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. New Engl J Med 2017;377(5):454-464.PMID: 28644114

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. New Engl J Med 2017;376(9):836-847.PMID: 28249141

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 2020;135(24):2137-2145.PMID: 32219442

Wei AH, Strickland SA, Hou J-, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study. J Clin Oncol 2019;37(15):1277-1284.PMID: 30892988

Moujalled DM, Brown FC, Chua CC, Dengler MA, ….., Wei AH. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood 2022 Oct 11: blood.2022016090.PMID: 36219880

Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, ….., Wei AH. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined with Modified Intensive Chemotherapy. J Clin Oncol 2020;38(30):3506-3517.PMID: 32687450

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, …., Wei AH. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 2019;33(4):905-917.PMID: 30214012

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140(12):1345-1377.PMID: 35797463

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, ….., Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424-447.PMID: 27895058

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.